Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent

Antiviral Therapy

Volumn 3, Issue SUPPL. 3, 1998, Pages 113-121

  Chu, C K ^a   Boudinot, F D ^a   Peek, S F ^a   Hong, J H ^a   Choi, Y ^a   Korba, B E ^a   Gerin, J L ^a   Cote, P J ^a   Tennant, B C ^a   Cheng, Y C ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 FLUORO 5 METHYL BETA LEVO ARABINOFURANOSYL)URACIL; ANTIVIRUS AGENT; ARABINOSE; DEOXYCYTIDINE KINASE; DNA POLYMERASE; LACTIC ACID; MITOCHONDRIAL DNA; NUCLEOSIDE; RIBOSE; THYMIDINE KINASE; UNCLASSIFIED DRUG; URACIL DERIVATIVE; XYLOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BIOAVAILABILITY; ENZYME INHIBITION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS VIRUS; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; RAT; WOODCHUCK;

ANIMALS; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; BIOLOGICAL AVAILABILITY; CELL LINE; DEOXYCYTIDINE KINASE; DRUG EVALUATION, PRECLINICAL; DUCKS; HEPADNAVIRIDAE INFECTIONS; HEPATITIS B VIRUS; HEPATITIS B VIRUS, DUCK; HEPATITIS B VIRUS, WOODCHUCK; HEPATITIS B, CHRONIC; LACTIC ACID; LETHAL DOSE 50; MARMOTA; MICE; PHOSPHORYLATION; RATS; THYMIDINE KINASE;

EID: 0031791448     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)